The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the publicly traded common stock of Express Scripts Holding Company (“Express Scripts” or the “Company”) (Nasdaq: ESRX) between February 24, 2015 and March 21, 2016, inclusive (the “Class Period”).

If you purchased or otherwise acquired the publicly traded common stock of Express Scripts during the Class Period, you may move the Court for appointment as lead plaintiff by no later than July 5, 2016. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Express Scripts investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Express Scripts Securities Class Litigation

Express Scripts is an independent pharmacy benefit manager (“PBM”) based in St. Louis, Missouri. As a PBM, Express Scripts administers the prescription drug benefit component of its customers’ health insurance plans. Express Scripts also negotiates drug prices with pharmacies and establishes a network of pharmacies through which patients can fill their prescriptions. Its most important client is Anthem, Inc. (“Anthem”), one of the largest health benefits companies in the United States.

On January 12, 2016, Anthem publicly threatened to terminate its relationship with Express Scripts and seek out another PBM partner unless Express Scripts would renegotiate its agreement with Anthem to deliver more than $3 billion in annual savings to Anthem. Indeed, Anthem’s statement made clear that Anthem and Express Scripts had engaged in contentious pricing negotiations for some time. On this news, the price of Express Scripts shares fell $5.89 per share, or 6.88% from a previous closing price of $85.58 on January 12, 2016, to close at $79.69 per share on January 13, 2016.

On March 21, 2016, Anthem initiated federal proceedings against Express Scripts alleging that Express Scripts had breached its contract with Anthem by failing to negotiate pricing terms in good faith, and that Express Scripts had materially breached its contractual obligation to perform operational duties in a “prudent and expert manner.” Anthem also revealed for the first time that it had been seeking to negotiate drug re-pricing since the beginning of 2015 and Express Scripts had been stalling those negotiations. On this news, the price of Express Scripts shares fell $1.82 per share, or 2.62% from a previous closing price of $69.34 on March 21, 2016, to close at $67.52 per share on March 22, 2016.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for thirteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Best Lawyers and U.S. News have named Lieff Cabraser as a “Law Firm of the Year” for each year the publications have given this award to law firms.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit http://www.lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.